Lu Luo

ORCID: 0000-0002-9151-6410 · 5 papers in corpus
article 2025
Risk factors for recurrent implantation failure as defined by the European Society for Human Reproduction and Embryology
Human Reproduction ·doi:10.1093/humrep/deaf042

STUDY QUESTION: What are the unrecognized risk factors for recurrent implantation failure (RIF) as defined in the ESHRE recommendation? SUMMARY ANSWER: Anti-Müllerian hormone (AMH) is the strongest predictor for RIF, followed by chronic en…

case-report 2023
Gonadotropin-releasing hormone agonist contributes to the successful implementation of in vitro fertilization in a patient with cervical endometriosis: a case report
AJOG global reports ·doi:10.1016/j.xagr.2023.100213

This is a case report of a nulliparous young woman who suffered from prolonged menstruation and infertility for 1 year. Magnetic resonance imaging and a transvaginal ultrasound examination revealed cervical endometriosis. Treatment with a g…

2023
Obstetric and neonatal outcomes after programmed frozen embryo transfer with or without GnRH agonist for polycystic ovary syndrome: secondary analysis results from a randomized controlled trial.
AJOG global reports ·doi:10.1016/j.xagr.2023.100201

BackgroundRecent studies have reported higher risks of adverse maternal and neonatal outcomes, such as hypertensive disorders of pregnancy, after programmed frozen embryo transfer, especially in cycles with gonadotropin-releasing hormone ag…

article 2020
Impact of Gonadotropin-Releasing Hormone Agonist Pre-treatment on the Cumulative Live Birth Rate in Infertile Women With Adenomyosis Treated With IVF/ICSI: A Retrospective Cohort Study
Frontiers in endocrinology ·doi:10.3389/fendo.2020.00318

Introduction:Although pre-treatment with a GnRH agonist can reduce the size of adenomyosis lesions, the supra-physiological hormone level induced by controlled ovarian hyperstimulation (COH) may negate the usefulness of the GnRH agonist in …

article 2010
The clinical significance of the serum estradiol-2,tumor necrosis factor-alpha and vascular endothelial growth factor in patients with endometriosis